Technology Applications
Molecular diagnostic assays generate excitement because they improve health care providers' ability to determine the cause of disease and prescribe targeted, effective treatments earlier, leading to lower mortality, improved patient management and outcomes and healthcare cost savings. Fast turn-around, accurate, reliable, pathogen identification and antibiotic susceptibility characterization enables rapid, effective treatment and improved clinical outcomes for critical care patients with septicemia or patients with multi-drug resistant infections such as tuberculosis or staphylococcus (MRSA) infections. GenArraytion's high fidelity signatures can be used to enhance and improve in vitro diagnostics systems and reagents, clinical laboratory services, and pharmaceutical preclinical and clinical trials for next generation anti-infective agents.
GenArraytion's approach to identifying and determining antibiotic susceptibility of pathogens will be a benefit to healthcare providers by providing timely, effective treatment and improving diagnosis and therapeutic monitoring. Initial diagnostic tests will target the hospital critical care market. Microbiological methods typically used to diagnose critically ill patients with septic infections require at least two days to identify and an additional two days to determine antibiotic sensitivity. Thus, doctors treat these critically ill patients with as many as ten antibiotics simultaneously until they receive definitive information. Our approach will reduce the time dramatically, enabling doctors to rapidly initiate treatment with an effective antibiotic, rather than using a broad-spectrum cocktail. A quick, accurate diagnosis will save lives, and decrease morbidity and recovery times. Improved outcomes will translate to faster bed turnover and higher hospital profits. In addition, accurate and timely antibiotic susceptibility information will decrease the cost of treatment and extend the useful lifetime of antibiotics.
GenArraytion's approach to identifying and determining antibiotic susceptibility of pathogens will be a benefit to healthcare providers by providing timely, effective treatment and improving diagnosis and therapeutic monitoring. Initial diagnostic tests will target the hospital critical care market. Microbiological methods typically used to diagnose critically ill patients with septic infections require at least two days to identify and an additional two days to determine antibiotic sensitivity. Thus, doctors treat these critically ill patients with as many as ten antibiotics simultaneously until they receive definitive information. Our approach will reduce the time dramatically, enabling doctors to rapidly initiate treatment with an effective antibiotic, rather than using a broad-spectrum cocktail. A quick, accurate diagnosis will save lives, and decrease morbidity and recovery times. Improved outcomes will translate to faster bed turnover and higher hospital profits. In addition, accurate and timely antibiotic susceptibility information will decrease the cost of treatment and extend the useful lifetime of antibiotics.
The same advantages that distinguish GenArraytion products and services in the medical diagnostic markets also apply to veterinary diagnostics, biological defense, epidemiological monitoring, environmental testing, and food and water safety. GenArraytion is working with collaborators and customers to develop capabilities in each of these market areas.
© 2008 GenArraytion, Inc. All Rights Reserved.
